Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients

Abstract

Our findings demonstrate that erlotinib is an effective neoadjuvant regimen in patients with <i>EGFR</i>-mutant locally advanced NSCLC, paving the way for its extended use in neoadjuvant settings.[ClinicalTrials.gov identifier: NCT01217619].